| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Actionable
answers
Guiding diagnosis, prognosis, and therapy options
Our comprehensive test menu includes testing to aid in providing both diagnostic and prognostic information, and in treatment selection across the full spectrum of malignancies. Each assay is developed and validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians. Through our clinical experience and expertise, we strive to provide testing options that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly oncology newsletter.
Additional test offerings
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
100+
genetic tests developed for solid tumors
9
areas of specialized oncology testing
20+
board-certified geneticists
specializing in molecular and
cytogenetic diagnostic testing
24/7
support from Mayo Clinic physicians and scientists
Diagnostic, prognostic, and predictive testing
Our comprehensive menu offers testing to provide diagnostic and prognostic information and helps guide treatment selection across the full spectrum of malignancies. Our tumor-specific panels only include genes that are clinically proven to impact patient outcomes. This eliminates confusing results, decreases the cost of testing, and leads to better patient care.
Integration of clinical care, pathology, genetics, and bioinformatics
We take the lead in designing and optimizing testing to guide patient care based on specific tumors. Our experience with clinical care is integrated with our expertise in pathology, genetics, and bioinformatics to direct which genes are selected for each panel and how these panels are used in a clinical setting.
Providing answers,
not just results
Genetic testing is about more than just determining whether a mutation is present or not. We take complex genetic results and turn them into clinically actionable answers. Our clinicians, laboratorians, and genetic counselors are available 24/7 to provide expertise and consultative support, eliminating the guesswork from results interpretation.
Webinar: Practical Aspects and Pitfalls of the Molecular Diagnosis of Brain Tumors
This “Specialty Testing” webinar will address practical aspects and pitfalls in the molecular diagnosis of brain tumors. All molecular testing platforms have factors that impact testing in the pre-analytical, analytical, and post-analytical phases. These factors will be discussed during the presentation and highlighted through clinical cases to illustrate the pitfalls in brain tumor molecular diagnosis encountered in the clinical practice at Mayo Clinic.
The Latest
PACE/State of CA/State of FL - This “Specialty Testing” webinar will discuss the collaborative effort which led to the discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.
The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.
Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.
Dr. Dollahite received world-class cancer treatment from a web of health care organizations, including Mayo Clinic in Rochester, Minnesota. Yet she never left New York; most of her treatment occurred in Ithaca. What made that possible was Cayuga Medical Center’s collaborative relationship with Mayo Clinic. Genetic testing at Mayo Clinic Laboratories provided important information about Dr. Dollahite’s cancer.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Genitourinary Pathology.